Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
ANNÉE
2022
AUTEURS
Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P, Canadian Cancer Trials Group and the Unicancer-GIPRODIGE Group
CONGRÈS/REVUE
JAMA Oncol
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES